Denosurel 120mg injection contains Denosumab, used to treat osteoporosis and avoid bone problems in cancer patients. By blocking the RANK ligand protein, it lowers the risk of fracture and bone loss. For patients with moderate renal impairment, monitoring renal function is recommended.

Brand Name: Denosurel

Composition: Denosumab

Mechanism of Action:

Denosumab acts by blocking RANKL, a protein involved in the erosion (breakdown) of bone. Denosumab enhances bone mass and decreases bone loss by inhibiting RANKL.

Uses:

• Osteoporosis
• Bone metastases
• Multiple myeloma
• Bone loss caused by hormone treatment for prostate or breast cancer

Dosage and Administration:

Given via subcutaneous injection, usually every 6 months for osteoporosis (Prolia) or more frequently (every 4 weeks) for cancer-related indications (Xgeva).

Side Effects:

• Joint pain
• Back pain
• Skin reactions at the injection site 
• Fatigue
• Hypocalcemia
• Increased risk of infections, particularly skin infections (e.g., cellulitis)
• Osteonecrosis of the jaw
• Fractures of the thigh bone 

Safety Advise:

Kidney  

Hypocalcemia is more common in patients with moderate to severe renal dysfunction. It's critical to regularly monitor kidney function. Do contact your Healthcare professional.

Liver   

Those with severe liver disease should use Esentra 120 Injection with caution. Esentra 120 Injection dosage adjustments can be required. Kindly speak with your healthcare provider.

Pregnancy  

Not recommended during pregnancy. Discuss risks with your doctor if you are planning to conceive.

Breast Feeding    

Using Denosurel 120 Injection while nursing is most likely dangerous. The medication may damage the unborn child if it enters the breastmilk, according to limited human data.

Storage:

Denosurel 120mg Injection should be stored in the refrigerator at a temperature between 2°C to 8°C (36°F to 46°F). Do not freeze it.

How should I use this Medication?

This medication is injected subcutaneously. It is delivered at a hospital or clinic by a medical professional. 

You will receive a personalized MedGuide prior to every treatment. Every time, make sure to carefully read this information.

Consult your pediatrician about Prolia and the usage of this medication in young patients. There might be a need for extra caution. Consult your physician about the usage of Xgeva in young patients. Precautions do apply even though this medication may be administered for specific diseases to youngsters as young as 13 years old.

References:

1.      Pageau SC. Denosumab. InMAbs 2009 May 1 (Vol. 1, No. 3, pp. 210-215). Taylor & Francis.

2.      Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. International journal of clinical practice. 2012 Dec;66(12):1139-46.

3.      Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert opinion on drug metabolism & toxicology. 2015 Mar 4;11(3):461-70.

4.      Narayanan P. Denosumab: A comprehensive review. South Asian journal of cancer. 2013 Oct;2(04):272-7.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Reliance Life Sciences

Address: Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Road, Rabale, Navi Mumbai 400 701

Country of origin: India